MarginsXMarginsX
Home › Markets › Health Care › OMER

Omeros Corporation (OMER)

OMER trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$16.68
-4.63% on the day
Market cap
$1.2B
Small cap
Revenue · 2020
$73.8M
-34.0% on 2019
Net income · 2020
-$138.1M
-187.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1285819/000155837021002177/0001558370-21-002177-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.

Profile

FieldValue
TickerOMER on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2009
SEC CIK0001285819
SEC industry codePharmaceutical Preparations
Incorporated inWA

Financials · 2020

LineValue
Revenue$73.8M
Net income-$138.1M
Operating income-$156.9M
Net margin-187.0%
Operating margin-212.6%
Revenue growth-34.0%
Cash$10.5M
Total assets$181.0M
P/E (computed)Net income was not positive
P/S (computed)16.4×

Warning signs

Cash runway
0.3 months
$2.0M cash at June 30, 2026
Share count, 1 year
+6.4%
2025-08-12 to 2026-08-07 · +15.2% over 3 years
Going-concern doubt
No
10-Q filed August 12, 2026
Insider net buying, 12 months
-$3.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-12
Cash and burn$2.0M cash; operating cash flow -$17.2M a quarter.Report 2026-06-30
Shares outstanding72,388,316 (2026-08-07); 68,055,826 a year earlier; 62,855,824 three years earlier.Cover page 2026-08-07
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Seattle, Washington, United StatesPCAOB Form AP 2026-04-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $3.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$28.5M$13.2M$4.1M$2.0MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
$9.9M$56.1M-$14.5M$1.9MNo debt tagsNeeds four quarters10-Q 2026-05-13
Q4 2025
2025-12-31
Not filed$86.5M-$39.8M$9.7M$87.9MNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$30.9M-$18.5M$2.4M$154.9MNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
$0-$25.4M-$21.9M$1.9M$154.9MNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
$0-$33.5M-$35.8M$4.3M$164.9MNeeds four quarters10-Q 2026-05-13
Q4 2024
2024-12-31
Not filed-$31.4M-$29.0M$3.4M$164.9MNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$32.2M-$32.1M$1.5M$164.9MNeeds four quarters10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-11-14
Latest annual report
FORM 10-K
10-K2026-03-31
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-16
Latest current report
FORM 8-K
8-K2026-11-16
Latest proxyDEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 812 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.4%
1 month-7.4%
3 months+0.8%
Year to date+1.8%
1 year+178.5%
From 52-week high-16.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OPKOPKO Health Inc.$1.62-3.57%$1.2B
KARDKardigan Inc.$12.85-7.02%$1.2B
SLNSilence Therapeutics Plc American Depository Share$19.80-0.15%$1.2B
AAPGAscentage Pharma Group International American Depository Shares$13.29-9.10%$1.2B
CMPSCOMPASS Pathways Plc American Depository Shares$8.27-8.21%$1.2B
AMPHAmphastar Pharmaceuticals Inc.$29.17-0.68%$1.2B
NKTRNektar Therapeutics$36.44-2.23%$1.2B
MNKDMannKind Corporation$3.96-4.24%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier